Ajay Kirtane and C. Michael Gibson discuss how orbital atherectomy compares with balloon angioplasty for severely calcified coronary arteries before DES implantation.

Does long-term colchicine benefit patients after acute MI? C. Michael Gibson and Sanjit Jolly discuss.

Mamas Mamas talks to Jacob Thomsen Lønborg about how PCI affects outcomes for patients with stable CAD undergoing TAVI.

Transcatheter devices are new to the heart failure (HF) community and treatment armamentarium for severe MR. This discussion focuses on the impact of transcatheter devices on HF patients and current barriers faced by referring specialists.

Johanne Silvain, Gilles Montalescot, and C. Michael Gibson discuss the effects of beta-blocker interruption in post-MI patients.

Patient selection is important for transcatheter interventions and impacts result success. This discussion focuses on defining what treatment goals should be, limitations of current interventions, and identifying appropriate transcatheter patients.

Paul Ridker and C. Michael Gibson discuss 30-year data hinting at how three modifiable factors—LDL, hs-CRP, and Lp(a)—might be leveraged to reduce long-term risk. 06f763f0-76e5-11f0-bb7c-8557ae1d8a8b

Clinical trials face challenges with variability in echo images, protocol adherence, and data quality. This discussion focuses on strategies to improve trial integrity, operational efficiency, and regulatory approval of transcatheter devices.

The Intrepid TMVR system just released 2-year transfemoral EFS outcomes at NY Valves. This discussion provides a deeper dive into what this data means for the Intrepid mitral program and perspectives on the transcatheter landscape.

Renate Schnabel, Ruben Casado Arroyo, and Mamas Mamas discuss the atrial fibrillation recommendations unveiled at ESC Congress 2024.